These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30284263)

  • 21. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.
    Bürzle M; Hubsch A; Spiegl N; Roten T; Marques A; Martig L; Shebl A; Stadler D
    Anal Biochem; 2020 Feb; 591():113534. PubMed ID: 31821802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
    Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
    Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: An open-label prospective trial.
    Akman AO; Kara FK; Koksal T; Cakir BC; Karagol C; Sayli T
    Transfus Apher Sci; 2017 Aug; 56(4):531-534. PubMed ID: 28818402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenesis and mechanisms of antibody-mediated hemolysis.
    Flegel WA
    Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
    Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
    Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
    Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An optimized microplate-based method to evaluate complement-dependent hemolysis mediated by intravenous immunoglobulins (IVIG).
    Wang Y; Khalenkov A; Scott DE
    Biologicals; 2022 Jul; 78():1-9. PubMed ID: 35842374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database.
    Berg R; Jacob D; Fuellenhals E
    Transfusion; 2015 Aug; 55(8):1847-54. PubMed ID: 25867204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of inflammation in intravenous immune globulin-mediated hemolysis.
    Pendergrast J; Willie-Ramharack K; Sampson L; Laroche V; Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S65-73. PubMed ID: 26174900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful ABO incompatible living donor liver transplantation in a patient with high isoagglutinin titer using high-dose intravenous immunoglobulin.
    Ikegami T; Taketomi A; Soejima Y; Iguchi T; Sanefuji K; Kayashima H; Yoshizumi T; Harada N; Maehara Y
    Transplant Proc; 2007 Dec; 39(10):3491-4. PubMed ID: 18089417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group O blood donors in Iran: evaluation of isoagglutinin titers and immunoglobulin G subclasses.
    Arabi S; Moghaddam M; Pourfathollah AA; Aghaie A; Mosaed M
    Immunohematology; 2021 Mar; 37(1):5-12. PubMed ID: 33962489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients.
    Parmentier SP; Rosenkranz E; Schirutschke H; Opgenoorth M; Quick C; Hoelig K; Rosner A; Hohenstein B; Hugo C; Passauer J
    Atheroscler Suppl; 2017 Nov; 30():253-256. PubMed ID: 29096846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis.
    Daw Z; Padmore R; Neurath D; Cober N; Tokessy M; Desjardins D; Olberg B; Tinmouth A; Giulivi A
    Transfusion; 2008 Aug; 48(8):1598-601. PubMed ID: 18466176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis].
    Cortey A; Elzaabi M; Waegemans T; Roch B; Aujard Y
    Arch Pediatr; 2014 Sep; 21(9):976-83. PubMed ID: 25125032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease.
    Tocan V; Inaba A; Kurano T; Sonoda M; Soebijanto K; Nakayama H
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):e100-e102. PubMed ID: 27879540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.
    Ucar İ; Koyuncu MB; Solmaz AA; Ugurludogan AC; Mercan S; Kucuk M; Unal T; Mazman S; Atilla E
    Transfus Clin Biol; 2023 Feb; 30(1):11-15. PubMed ID: 36028153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity.
    Thorpe SJ; Fox BJ; Dolman CD; Lawrence J; Thorpe R
    Vox Sang; 2003 Aug; 85(2):80-4. PubMed ID: 12925158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.